Company Announcements
Result of AGM
Related Companies
By LSE RNS
9 May 2017
PureTech Health plc
Results of Annual General Meeting
The Annual General Meeting of PureTech Health plc ("PureTech", LSE: PRTC) plc was held at 17.00 BST on Monday 8 May 2017. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll.
The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.
|
Resolutions |
For |
% |
Against |
% |
Withheld |
Total votes cast |
|
001. To approve the Company's Annual Report and Accounts for year end 31 December 2016 |
179,399,131 |
100.00 |
0 |
0.00 |
0 |
179,399,131 |
|
002. To approve the Directors' Remuneration Report |
174,260,790 |
97.14 |
5,138,341 |
2.86 |
0 |
179,399,131 |
|
003. To elect Mr. Joichi Ito as a Director |
179,399,131 |
100.00 |
0 |
0.00 |
0 |
179,399,131 |
|
004. To elect Dr. Raju Kucherlapati as a Director |
179,399,131 |
100.00 |
0 |
0.00 |
0 |
179,399,131 |
|
005. To elect Dr. John LaMattina as a director |
179,399,131 |
100.00 |
0 |
0.00 |
0 |
179,399,131 |
|
006. To elect Dame Marjorie Scardino as a director |
179,399,131 |
100.00 |
0 |
0.00 |
0 |
179,399,131 |
|
007. To elect Mr. Christopher Viehbacher as a director |
179,399,131 |
100.00 |
0 |
0.00 |
0 |
179,399,131 |
|
008. To elect Dr. Robert Langer as a director |
175,561,073 |
97.95 |
3,665,851 |
2.05 |
172,207 |
179,226,924 |
|
009. To elect Dr. Bennett Shapiro as a director |
173,797,010 |
96.97 |
5,429,914 |
3.03 |
172,207 |
179,226,924 |
|
010. To elect Ms. Daphne Zohar as a director |
179,399,131 |
100.00 |
0 |
0.00 |
0 |
179,399,131 |
|
011. To elect Mr. Stephen Muniz as a director |
179,399,131 |
100.00 |
0 |
0.00 |
0 |
179,399,131 |
|
012. To reappoint KPMG LLP as Auditors of the Company |
179,399,131 |
100.00 |
0 |
0.00 |
0 |
179,399,131 |
|
013. To authorise the Board of Directors to determine the Auditors' remuneration |
179,399,131 |
100.00 |
0 |
0.00 |
0 |
179,399,131 |
|
014. To authorise the allotment of shares |
173,622,534 |
96.78 |
5,776,597 |
3.22 |
0 |
179,399,131 |
|
015. To dis-apply pre-emption rights |
179,109,365 |
99.84 |
289,766 |
0.16 |
0 |
179,399,131 |
|
016. To dis-apply pre-emption rights in limited circumstances |
173,622,534 |
96.78 |
5,776,597 |
3.22 |
0 |
179,399,131 |
|
017. To authorise market purchase of own shares |
179,109,365 |
99.84 |
289,766 |
0.16 |
0 |
179,399,131 |
|
018. To authorise general meetings to be called on not less than 14 clear days' notice |
178,716,991 |
99.62 |
682,140 |
0.38 |
0 |
179,399,131 |
Due to its shareholding in the Company, Invesco Asset Management Limited is deemed to be a controlling shareholder as defined in the Financial Conduct Authority's Listing Rules. Accordingly, each resolution to elect an independent director (resolutions 4, 5, 6 and 7) has under Listing Rule 9.2.2E been approved by a majority of the votes cast by:
· the shareholders of the Company as a whole; and
· the independent shareholders of the Company, that is, all the shareholders entitled to vote on each resolution excluding the controlling shareholder as shown below.
|
Resolutions |
For |
% |
Against |
% |
Withheld |
Total votes cast |
|
004. To elect Dr. Raju Kucherlapati as a Director |
103,602,134 |
100 |
0 |
0 |
0 |
103,602,134 |
|
005. To elect Dr. John LaMattina as a director |
103,602,134 |
100 |
0 |
0 |
0 |
103,602,134 |
|
006. To elect Dame Marjorie Scardino as a director |
103,602,134 |
100 |
0 |
0 |
0 |
103,602,134 |
|
007. To elect Mr. Christopher Viehbacher as a director |
103,602,134 |
100 |
0 |
0 |
0 |
103,602,134 |
Notes:
A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
As at 8 May 2017, the number of issued shares in the Company was 237,387,951 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company's website www.puretechhealth.com and on the National Storage Mechanism.
In accordance with Listing Rule 9.6.2, a copy of the resolutions, other than those concerning ordinary business has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM.
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines that modulate the adaptive human systems. PureTech's therapies target the dysfunctions in the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. The Company is advancing a rich pipeline that includes multiple human proof-of-concept studies and pivotal or registration studies expected to read out over the next 12-18 months. PureTech Health's growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts, who along with PureTech's experienced team and a stellar Board identify, analyse and advance very selectively the opportunities the Company believes hold the most promise for patients. This experienced and engaged team places PureTech Health at the forefront of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
|
|
PureTech Health |
FTI Consulting |
|
|
Allison Mead +1 617 651 3156 amead@puretechhealth.com |
Ben Atwell, Matthew Cole, Rob Winder +44 (0) 20 3727 1000 |
This information is provided by RNS
You are here: news > regulatory news
10 Lower Thames St,
London EC3R 6EN